Stock AnalizKymera Therapeutics, Inc. KYMR
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Kymera Therapeutics, Inc. (KYMR) is a healthcare company listed in the US with a market value of about $10.9B. In the twelve months to September 30, 2026 it had revenue of $102M and net income of -$349M, a net margin of -341.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 3% a year, a 5-year average ROIC of -23%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $39M | $47M | $79M | $47M | $73M | $34M | $3M |
| Net income | -$349M | -$311M | -$224M | -$147M | -$155M | -$100M | -$46M | -$41M |
| Free cash flow | -$289M | -$234M | -$207M | -$137M | -$156M | -$131M | $79M | $17M |
| EPS (diluted) | $-3.63 | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | $-24.28 |
| Net margin | -341.8% | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | -1405.8% |
| ROIC | — | -21.1% | -22.5% | -27.4% | -25.2% | -16.7% | -12.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 23 analysts is $145.22, 14% above the current price; targets range from $116.00 to $180.00; the consensus rating is “Strong buy”; expected EPS is $-3.93 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Kymera Therapeutics pay a dividend?
Not currently.
Is Kymera Therapeutics a good stock to buy?
We do not give buy or sell advice. Kymera Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.